Amicus Therapeutics (NASDAQ:FOLD) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Valuation and Earnings
This table compares Amicus Therapeutics and Acura Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amicus Therapeutics||$91.25 million||30.66||-$348.99 million||($1.33)||-8.26|
|Acura Pharmaceuticals||$410,000.00||17.43||-$3.84 million||N/A||N/A|
Volatility and Risk
Amicus Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Amicus Therapeutics and Acura Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amicus Therapeutics currently has a consensus target price of $20.98, suggesting a potential upside of 91.09%. Given Amicus Therapeutics’ higher possible upside, analysts clearly believe Amicus Therapeutics is more favorable than Acura Pharmaceuticals.
This table compares Amicus Therapeutics and Acura Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Amicus Therapeutics beats Acura Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.